arrow_back Back Filing freshness 20-F FY 2025 SEC EDGAR

download Export Data

NovaBridge Biosciences

NBP

$1.52 ▼ -0.07 (-4.40%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Neutral

auto_awesome

Analytical Summary

NovaBridge Biosciences shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $334.8M

Dividend Yield —

Revenue Growth None

Op. Margin —

ROIC -40.8% ↘

FCF / Share None

Trailing P/E —

Price / Book 1.8x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$3.89M

↑ +112.1% —

Net Income Profit after all expenses

$-46.27M

↓ -108.1% —

FCF / Share Free cash flow per share

$-0.97

↓ -10.4% —

Health Breakdown

Returns ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 5 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Revenue Growth YoY (%)	—	—	N/M	N/M	-94.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1277%)	5386.7% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+67234%)	—	—
EPS Growth YoY (%)	-75.0% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	88.9% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	43.7% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	8.1% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	N/M	N/M	—	—
Net Income Growth YoY (%)	-108.1% Weak ↓ Weak Declining Year-over-year change in net income	89.2% Excellent ↑ Excellent Improving Year-over-year change in net income	43.2% Excellent Excellent Year-over-year change in net income	0.6% Caution Caution Year-over-year change in net income	N/M	N/M	—	—
FCF Growth YoY (%)	—	—	-10.4% Weak Weak Year-over-year change in free cash flow	2.6% Caution Caution Year-over-year change in free cash flow	N/M	—	—	—
Revenue CAGR 3Y (%)	—	—	-74.6% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Effective Tax Rate (%) (%)	0.0% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—
Profit Margin (%) (%)	—	—	—	—	—	30.5% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+154%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	27.6% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	—	—	0.90x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.46x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.43x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.90x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.61x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Return on Invested Capital (%)	-40.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-25.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—	—	—
Return on Capital (%) (%)	-36.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	-24.2% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—	—	—
Return on Common Equity (%) (%)	-20.0% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-234%)	-11.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-174%)	-85.3% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-669%)	-86.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-674%)	-51.1% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-441%)	8.4% Caution Caution Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-44%)	71.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+376%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Debt to Equity (x)	—	—	0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-97%)	0.01x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-99%)	—	—	-0.02x Excellent Excellent Total debt relative to shareholder equity Optimal: < 0.6x vs Sector: Below avg (-104%)	—
Net Debt (USD)	$-210.63M	$-68.26M	$-297.39M	$-463.24M	$-552.93M	$-729.32M	$-156.21M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Revenue per Share (USD)	—	—	$0.02	$-0.17	$0.08	$1.76	—	—
Basic EPS, GAAP (USD)	$-0.21	$-0.12	$-1.08	$-1.92	$-2.09	$0.54	$-28.90	—
Free Cash Flow per Share (USD)	—	—	$-0.97	$-0.88	$-0.90	$0.49	—	—
Book Value per Share (USD)	$0.87	$1.07	$1.30	$2.21	$3.89	$5.23	$-34.94	—
Tangible Book Value per Share (USD)	$0.87	$1.07	$1.21	$2.00	$3.65	$4.97	$-40.29	—
Basic Weighted Avg Shares (shares)	220.26M	186.73M	191.42M	189.79M	174.71M	134.16M	—	6.53M

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Working Capital (USD)	$190.63M	$168.24M	$271.11M	$415.87M	$652.44M	$730.66M	$111.01M	—
Total Equity (USD)	$230.94M	$201.16M	$242.00M	$421.90M	$715.50M	$862.40M	$-292.26M	—

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 20-F ↗	FY 2024 Dec 31, 2024 20-F ↗	FY 2023 Dec 31, 2023 20-F ↗	FY 2022 Dec 31, 2022 20-F ↗	FY 2021 Dec 31, 2021 20-F ↗	FY 2020 Dec 31, 2020 20-F ↗	FY 2019 Dec 31, 2019 20-F ↗	FY 2018 Dec 31, 2018 20-F ↗
Sales/Revenue/Turnover (USD)	—	—	$3.89M	$-32.12M	$13.81M	$236.42M	$4.31M	—
Depreciation Expense (USD)	$68.00K	$261.00K	$3.40M	$3.70M	$2.16M	$1.95M	$1.41M	—
Net Income, GAAP (USD)	$-46.27M	$-22.23M	$-206.44M	$-363.53M	$-365.87M	$72.17M	$-208.56M	—
Operating Cash Flow (USD)	—	—	$-183.80M	$-159.89M	$-152.70M	$66.45M	$-124.68M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 8 quarters

NovaBridge Biosciences

Analytical Summary

8-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare NBP with peers